Chapter 62: Adult Musculoskeletal Medications

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So think about this for a second.

If you take a pill to fix a, you know, a crumbling bone,

could it like accidentally destroy your esophagus on the way down?

I mean, we usually prefer medicine to be super precise, like structural engineering or something.

Right, right.

Like you break your arm, the x -ray shows that jagged white line and the provider just points and says, there it is.

Exactly.

Broken or not broken, it's clean, it's visible.

And frankly, it's comforting.

Yeah, it really is.

But the moment you step into the world of musculoskeletal pharmacology, that straightforward x -ray machine just, well, it effectively breaks down.

Oh, entirely.

You are suddenly looking at a clinical landscape where the real problems are microscopic or metabolic or even wait for it, driven by the body's own immune system turning against itself.

Which is terrifying when you think about it.

It really is.

Well, welcome to this deep dive.

And hey, if you are listening to this right now, I am speaking directly to you, the nursing student gearing up for the NCLEX.

We know you're in the thick of it right now.

Absolutely.

Consider this your one -on -one, highly focused tutoring session.

Today, our Saunders Comprehensive Review.

Specifically focusing on musculoskeletal medications.

Right.

And our mission today isn't just to help you memorize a giant list of drug names.

That doesn't work.

We want to understand the underlying why and how behind these medications.

Because that's how you actually anticipate the priority safety risks.

Exactly.

So to make sure this information actually sticks, we are going to move through the body chronologically.

Right.

Starting at the outer layers, the muscles.

We'll look at skeletal relaxants.

Then we move deeper into the joints, exploring the metabolic crisis of gout and the autoimmune battlefield of rheumatoid arthritis.

From there, we dive into the structural foundation itself.

The bones.

Looking at osteoporosis.

And then we wrap up with the universal symptom that ties all of this together, which is pain management.

But before we get to the muscles, we really need to establish the golden rule of NCLEX preparation.

Oh, this is so crucial.

To truly ace this exam,

foundational concepts have to support your clinical reasoning.

Right.

And that clinical reasoning drives your priority decisions.

Which ultimately ensures safe patient care.

That's the whole point of the exam.

Safe patient care.

Okay, let's unpack this.

Starting with our first layer, the muscles.

Let's do it.

So when we look at skeletal muscle relaxants, we're talking about drugs used to calm severe spasms or spasticity.

Right.

Which could be from an acute injury, like a patient tweaking their lower back while moving heavy furniture.

Or it could be from chronic, really debilitating central nervous system disorders, like multiple sclerosis, a previous stroke, cerebral palsy, things like that.

Yeah.

And the text breaks these down into two main pathways.

They either act peripherally or they act centrally.

The peripheral pathway is actually fairly straightforward, right?

It is, yeah.

Medications acting peripherally interfere directly with the calcium release from the muscle tubules.

Because calcium is the trigger for muscle fiber contraction.

Exactly.

So if you block that release, you physically stop the muscle from spasming.

It's localized.

But the central acting relaxants operate on a much, much broader scale.

Oh, completely.

They essentially depress neuron activity across the entire central nervous system.

I always think of centrally acting relaxants like walking over and putting a dimmer switch on the body's entire nervous system.

That's a great analogy.

Right.

You're turning down the global voltage just so that those specific localized muscles stop misfiring.

But I have to push back here on the logic of this treatment.

OK.

What do you mean?

Well, if a patient comes in with a localized muscle spasm in their shoulder and we treat it by dimming the lights on their entire brain and spinal cord, isn't that a massive systemic safety risk just to fix the local problem?

Oh, it is an enormous safety risk.

And the source material highlights this constantly.

Because you're not just relaxing a shoulder muscle?

No, not at all.

You introduce a cascade of systemic adverse effects.

We're talking about severe dizziness, profound drowsiness, overall muscle weakness.

And dangerous drops in blood pressure.

Exactly.

Hypotension is a huge issue.

So because of this physiological reality, your priority nursing interventions shift entirely towards safety and fall prevention.

You absolutely must assess the patient's risk for injury.

Right.

You have to instruct them to avoid any activities requiring alertness, like driving.

And most critically,

they cannot, under any circumstances, introduce any other chemical that further depresses that system.

No alcohol, no opioids, no barbiturates, and no sedatives.

Period.

Let's look at a clinical scenario the text uses to test this, because it's a big one.

Yeah, the baclofen question.

Right.

Imagine you are doing discharge teaching for a patient receiving baclofen, which is classic centrally acting relaxant.

They're taking it for a skeletal muscle injury.

The most critical instruction you can give them is to avoid the use of alcohol.

Because baclofen and alcohol together create a really deadly synergistic effect.

You're stacking two central nervous system depressants.

Exactly.

Which can dangerously suppress respiratory drive and cognitive function.

It's incredibly unsafe.

Now, while we are on the subject of baclofen, there is this profound safety alert in the book regarding how it's administered.

Oh, the intrathecal pumps, yes.

Yeah.

Because baclofen is sometimes delivered continuously via an implantable pump directly into the spinal fluid for chronic spasticity.

Right.

And if you have a patient with one of these pumps, maintaining their medication refill appointments is literally a matter of life and death.

Because if that pump runs dry, the sudden absence of the drug just throws the nervous system into total chaos.

The rebound effect is incredibly severe.

What does that look like clinically?

Well, the patient can experience sudden life -threatening withdrawal symptoms.

That includes an exaggerated return of their spasticity, hyperthermia, and even severe seizures.

Wow.

So pump refills are strictly non -negotiable.

Absolutely non -negotiable.

Let's shift to a medication that acts differently.

Danturline.

Ah, yes.

This one acts directly on the skeletal muscles to relieve spasticity rather than dimming the entire central nervous system.

Right.

It's peripheral.

So logically, if it's localized to the muscle, the side effect profile should be safer, right?

You would think so, but pharmacology rarely stays localized.

It always finds a way to complicate things.

It really does.

Even though danturline acts on the muscle tissue, the medication still has to be macabalized systemically by the body.

Right.

And the hidden danger here is hepatic.

Exactly.

Dose -related liver damage is the most serious, potentially fatal adverse effect of danturline.

So if a test scenario asks you which laboratory value would identify a complication of danturline therapy, you completely bypass the muscle enzymes and go straight to liver function tests.

You have to.

You must monitor liver function values routinely before starting the therapy and continually during treatment.

Liver toxicity is actually a pervasive theme for muscle relaxants in general, isn't it?

It is, because they are heavily metabolized in the liver and then excreted by the kidneys.

So drugs like tizanidine, metaxalone, and cloroxazone.

They're all strictly contraindicated in patients with severe liver, renal, or heart disease.

Okay, speaking of strict contraindications,

there is a really fascinating clinical judgment scenario in the text regarding cyclobenzeprine.

Oh, the MAOI interaction.

Yes.

Imagine you check a patient's chart before administering their newly prescribed cyclobenzeprine for a back spasm, and you notice they are currently taking phenylzine, which is a monoamine oxidase inhibitor, or an MAOI for depression.

That requires an absolute immediate halt.

Why is it so dangerous?

A cyclobenzeprine is strictly contraindicated if a client has received any MAOIs within the last 14 days.

14 days, wow.

Yeah.

The interaction between these two classes can trigger a massive hypertensive crisis or severe serotonin syndrome.

So you withhold the dose, notify the provider immediately, and document the intervention.

Exactly.

But the complications with cyclobenzeprine don't even stop there.

Right.

It also has significant anticholinergic effects.

It acts very much like atropine, basically drying the body out.

Because of this, the text points out that it must be used with extreme caution in patients with a history of urinary retention or angle closure glaucoma.

And the pathophysiology of that glaucoma connection is totally crucial for the NCLEX.

Let's break that down.

How does a muscle relaxant affect the eye?

Well, anticholinergic medications cause smooth muscle relaxation, right?

Which leads to pupillary dilation.

When the pupil dilates, the iris bunches up, and that can physically block the drainage angle in the eye.

Oh, I see.

So for a patient who already has angle closure glaucoma, this sudden blockage causes their interocular pressure to just spike to blinding levels.

Precisely.

It's a perfect example of why cyclobenzeprine is generally restricted to short -term therapy of just like two to three weeks.

That is a brilliant connection to make.

Okay, before we leave the muscles entirely, I want to touch on the intravenous administration of metacarbamol.

Yeah, the IV form requires a lot of caution.

If a nurse pushes the parenteral form of metacarbamol too rapidly, the sudden influx of the drug can cause dangerous bradycardia and severe hypertension.

You also have to watch the IV site like a hawk for extravization.

Because if this medication leaks into the surrounding tissue, it causes severe tissue sloughing and necrosis.

It is a very harsh drug on the veins.

And as part of your patient education, you also need to prepare them for a very alarming but entirely harmless side effect.

Oh, the urine color change, yes.

As the liver metabolizes metacarbamol and the kidneys excrete the byproducts, those metabolites actually oxidize.

Which can cause the patient's urine to turn brown, black, or even dark green.

I mean, I can only imagine a patient's panic if they go to the bathroom and see green urine without any prior warning.

You definitely have to warn them.

Okay, let's transition.

We've seen how to call misfiring muscle fibers.

But what happens when the issue isn't a muscular spasm, but a localized metabolic crisis?

Like a joint space filled with microscopic jagged needles shredding the tissue from the inside out.

What a visual.

But that brings us to section two, antigoat medications.

Gout is basically a master class in metabolic dysfunction.

How so?

Well, the human body breaks down purines, which are found in certain foods and our own cells.

And the byproduct of that breakdown is uric acid.

In a patient with gout, either their body produces way too much uric acid or their kidneys fail to excrete enough of it.

So it builds up.

Right.

That excess uric acid crystallizes in the joints, causing an excruciating fiery inflammatory response.

So the pharmacological strategy with medications like allopurinol, colchicine, and probenacid is to interrupt that process.

By either reducing uric acid production directly or forcing the kidneys to excrete more of it.

Here's where it gets really interesting regarding our nursing interventions.

If a patient is placed on allopurinol to lower those uric acid levels, the text is incredibly adamant that we must instruct them to drink 2000 to 3000 milliliters of fluid every single day.

That's a lot of fluid.

It is.

Why are we forcing these patients to consume up to three liters of water?

To physically flush the plumbing, so to speak.

Flush the plumbing.

I like that.

Yeah, because when these medications force the body to excrete high volumes of uric acid into the urinary tract, you run a very high risk of that concentrated uric acid crystallizing inside the kidneys themselves.

Which forms incredibly painful urate stones.

Right.

So a massive fluid intake dilutes the urine and keeps the renal system flushed, moving the waste out of the body before it has time to solidify.

That physiological mechanism actually explains another major warning in the text.

Patients on allopurinol shouldn't take large doses of vitamin C.

Ah, yes.

Because vitamin C naturally acidifies the urine.

And uric acid crystals form much more rapidly in an acidic environment.

Acidic urine practically invites kidney stones.

Definitely.

Patients also need to schedule annual eye examinations because prolonged allopurinol use can cause visual changes and macular damage.

Good to know.

But let's talk about a massive NCLE X -trap the text warns about regarding pain management for gout, the aspirin rule.

Oh, this is an area where clinical reasoning is vital.

You must explicitly caution your gout patients never to take aspirin to manage their joint pain.

Never.

But wait, why?

Aspirin is an anti -inflammatory, so logically you'd think it would help a fiery joint.

You'd think so.

But low doses actually inhibit the kidneys from secreting uric acid into the urine.

Yeah, it competes for the exact same excretion pathways, causing the uric acid to be retained in the bloodstream.

Taking aspirin can actually trigger or worsen a severe gout attack.

So if they have a headache or mild pain, we instruct them to use acetaminophen instead.

Exactly.

And we can't ignore the dietary component either.

Right.

Since uric acid comes from the breakdown of purines, part of the nurse's job is nutritional education.

You must instruct the client to avoid foods that are exceptionally high in purines.

What are we talking about here?

That includes wine, alcohol, organ meats,

sardines, salmon, scallops, and rich grazies.

So no surf and turf with wine.

Definitely not.

Now, what about a patient experiencing an acute gout attack right now?

We often see colchicine prescribed for that.

Yes, colchicine is very common for acute attacks.

There's a scenario in the text highlighting that colchicine must be used with extreme caution in older adults and those with kidney disease.

Because colchicine alters the way white blood cells respond to the uric acid crystals, which is what reduces the inflammation.

But it has a very narrow therapeutic window.

Meaning it gets toxic fast.

Very fast.

And it can be highly toxic to the gastrointestinal tract.

So the golden nursing rule for colchicine is this.

If the patient develops severe gastrointestinal symptoms, nausea, vomiting, diarrhea, or abdominal pain,

you must withhold the medication and notify the primary health care provider immediately.

It is often the very first sign of systemic toxicity.

Don't ignore GI symptoms on colchicine.

Got it.

Okay, so we've seen how metabolic waste like uric acid can physically crystallize and shred a joint from the inside out.

But what happens when the joint is being destroyed not by waste, but by the body's own defense system?

That brings us to section three.

The autoimmune battlefield of rheumatoid arthritis.

The progression of rheumatoid arthritis, or RA, is entirely different from gout.

The text provides a really vivid illustration of this pathophysiological progression.

It starts with inflammation in the synovial membrane that lines the joint.

Right.

And if that inflammation goes unchecked, it triggers the formation of something called PANAS.

PANAS.

It sounds like such a clinical, harmless word, but the reality of it is terrifying.

It really is.

It's this aggressive, invasive sheet of inflamed granulation tissue that acts almost like a weed choking a garden.

That's a very accurate way to describe it.

That PANAS spreads aggressively and secretes enzymes that literally erode the articular cartilage.

So the padding is just eaten away.

Exactly.

As the cartilage deteriorates, the bone ends are exposed and damaged.

Eventually, the joint cavity is completely destroyed, leading to calcification and the permanent fusion of the articulating bones.

The joint is effectively locked in place.

Yes.

Because of this destructive cascade, the text makes it clear that the only way to preserve joint function is through early diagnosis and highly aggressive pharmacological treatment.

Which brings us to the heavy hitters of this chapter.

DR -mards, or disease modifying antichromatic drugs, and biologic DR -mards.

We are talking about major drugs like methotrexate, leflunomide, etanercept, and influximab.

Their entire purpose is to slow down or halt that degenerative PANAS formation.

But to understand how to care for these patients, you must understand the severe physiological trade -off we are making.

Because to save the joint from this relentless autoimmune attack, DR -mards intentionally suppress the entire immune system.

Therefore, for the nurse, monitoring for infection becomes the absolute highest priority.

There's a perfect clinical test of this concept in the text.

A client is receiving etanercept, a biologic DR -m for rheumatoid arthritis.

The nurse has to prioritize an assessment.

Now, I know that localized injection site reactions are incredibly common with these subcutaneous biologics.

Shouldn't monitoring that site be the priority?

Injection site reactions are common, yes, but they are not immediately life -threatening.

Right.

The true danger of generalized immune suppression is bone marrow suppression, which leads to pancytopenia.

A dangerous drop in all blood cells.

Exactly.

The appearance of abnormal white blood cell counts, plunging neutrophils, and low platelet counts alerts the nurse to a potentially fatal systemic infection or severe hematological bleeding disorder.

So you must monitor WBCs and platelets rigorously before and during treatment?

You absolutely have to.

The nursing education required here is massive, too.

We have to teach these patients that they are severely immunocompromised.

They need to consult their provider before receiving any live vaccines.

Right.

And they must proactively avoid crowds or anyone with an active infection.

So we're suppressing their immune system, putting them at incredible systemic risk, all to save the joint.

How do we even know if the risk is paying off?

I mean, how does the nurse evaluate if the DRV is actually working?

Yeah, exactly.

Well, you have to look for a combination of clinical and diagnostic markers.

First, you want to see a reduction in symptoms during periods of emotional stress.

Because stress frequently exasperates RA flares.

Right.

Second, you want to see normal white blood cell, platelet, and neutrophil counts.

Which confirms we haven't pushed the immunosuppression too far into that dangerous pancytopenia territory.

Exactly.

Third, you want to measure an increased range of motion in the affected joints after about three months of therapy.

And fourth.

The ultimate goal.

Radiological findings that show absolutely no progression of joint degeneration.

The x -ray should prove that the bone fusion has been halted.

Incredible.

Okay, we've calmed the muscles, we've flushed out the joints, and we've halted the autoimmune attack on the cartilage.

Now we move to section four.

We have to look at the foundational scaffolding holding this entire system together.

The bones themselves.

Specifically treating osteoporosis.

Osteoporosis is characterized by a silent progressive decrease in bone mass,

which leads to increased bone fragility.

So the core treatment goal is straightforward.

Reduce the occurrence of catastrophic fractures by maintaining or actively increasing bone strength.

The text essentially breaks the pharmacology down into two distinct strategies.

It's basically like we're either laying down brand new concrete or we are spraying a chemical sealant to stop the existing concrete from crumbling away.

That analogy maps perfectly to the cellular level.

Terraparatite, for example, is the new concrete.

How does it work?

It's a synthetic portion of the human parathyroid hormone that actively stimulates new bone formation by increasing the action of osteoblasts.

The cells that build bone.

Right.

It's very powerful and usually reserved for clients at extreme risk for fractures.

On the other side you have the sealants, the anti -absorptive medications.

These drugs inhibit the osteoclasts, which are the cells responsible for breaking bone down.

And this broad category includes your bisphosphonates, right?

Like alendronate, rise -burnet, and ibandrinate.

Yes.

And when it comes to the NCLEX,

bisphosphonates carry one of the most famous, heavily tested safety alerts in all of pharmacology regarding how they are administered.

Oh, absolutely.

If a patient is prescribed alendronate, the nurse must instruct them to take the medication on a completely empty stomach with a full glass of water.

And critically, they must remain sitting or standing strictly upright for at least 30 minutes following administration.

For ibandrinate, they must stay upright for 60 minutes.

Why are the rules so incredibly rigid here?

Because of the devastating physical damage these pills can inflict on the way down.

The esophagus connection from the intro.

Exactly.

Bisphosphonates are highly caustic and can cause severe esophageal irritation, ulceration, and erosive esophagitis.

Gravity is literally the only thing protecting the patient's esophagus.

So taking it on an empty stomach with a full glass of water ensures the pill is rapidly swept into the stomach.

And remaining upright prevents the medication from refluxing back into the esophageal tract.

Which means if a client has an esophageal disorder that impedes swallowing, or if they are physically incapable of sitting or standing upright for that 30 -minute window.

These medications are entirely contraindicated.

Wow.

Okay.

There's one more anti -resorptive medication I want to highlight.

Because the clinical reasoning behind it is fascinating.

Riloxaphene.

It's a non -bisphosphonate, so we don't have the esophageal rules here.

Right.

But the critical safety rule is that Riloxaphene is absolutely contraindicated in clients who have a history of venous thrombotic events.

Like deep vein thrombosis or pulmonary embolisms.

Because Riloxaphene increases blood coagulability.

And because of that severe thrombotic risk, the text emphasizes that the medication needs to be discontinued 72 hours prior to any period of prolonged immobilization.

If we think about Versa's triad for blood clots, stasis of blood flow combined with

hypercoagulability is just a recipe for disaster.

So if a patient is going on extended bed rest after a major surgery, or even traveling for a long period on a cross -country flight.

The nurse must ensure the Riloxaphene is stopped three days beforehand to prevent a massive clot from forming.

It is the perfect example of clinical reasoning leading directly to safe patient care.

It truly is.

Which brings us to the final piece of the musculoskeletal puzzle.

Yes, section 5.

Because regardless of whether the patient is suffering from a back spasm, crystallized gout, the erosion of rheumatoid arthritis, or the fragility of an osteoporotic fracture, there is one universal symptom they will all experience.

Musculoskeletal pain.

Yep.

Fortunately, the pharmacology here is beautifully simple, which is a welcome relief after navigating the complexities of DMARDS and bisphosphonates.

For real.

For general musculoskeletal pain, non -steroidal anti -inflammatory drugs,

your NSAIDs like ibuprofen, naproxen, and silicoxib along with acetaminophen remain the foundational first -line treatments.

And depending on the pathophysiology of the injury, the provider will often supplement those first -line treatments with the skeletal muscle relaxants we discussed at the very beginning of our session.

It just brings everything full circle.

Okay, let's take a breath and synthesize the why of the journey we just went on.

A lot of ground covered.

We started by dimming the entire central nervous system to calm misfiring muscle spasms, which taught us to keep a hypervigilant eye on systemic safety risks like profound drowsiness and silent liver toxicity.

Then we moved into the joint space, forcing 3 ,000 milliliters of fluids through our gout patients to flush out uric acid sludge before it could crystallize into kidney stones.

Then we made the incredibly high -stakes trade -off of suppressing the patient's entire immune system with diarns just to halt panis formation and save an arthritic joint.

And finally, we used the simple force of gravity, sitting our osteoporosis patients straight up in a chair with a full glass of water so their bisphosphonates could protect their crumbling bones without burning a hole through their esophagus.

When you anchor the pharmacology to the underlying pathophysiology and those primary safety risks, it transforms from a random list of drug names into a highly logical sequence of nursing actions.

And that deep understanding is exactly how you conquer Chapter 62.

But before we let you get back to your studying, our expert has one final provocative thought to leave you with.

A clinical puzzle to mull over as you continue your prep.

If you look ahead to the end of the source text, there is a pyramid to success for Unit 7 -7, which covers immune problems of the adult client.

Consider the massive physiological trade -off we've just spent so much time discussing.

How DMARDs intentionally suppress the immune system to treat rheumatoid arthritis.

We as healthcare providers are deliberately inducing a dangerous immunocompromised state.

This raises a profound clinical question.

What happens when the immune system is inherently deficient on its own?

Not from a controlled medication, but from a relentless virus, like with HIV AIDS.

How does the nurse protect a patient whose body naturally cannot fight back against the environment?

And perhaps even more challenging for your nursing practice, how do you manage the deep psychosocial isolation, the fear, and the body image disturbances that accompany severe systemic immune disorders?

That is the next great conceptual puzzle for you to explore in your studies.

A brilliant connection between the chapters.

The human body is an astonishing, deeply complicated machine.

And you are doing the hard, necessary work to learn exactly how to protect it.

Thank you for joining us for this session.

From all of us on the Last Minute Lecture team here at the Deep Dive, you've got this.